インドの胃がん治療市場：治療タイプ別、タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測、2019年～2033年

インドの胃がん治療の市場規模は、2026年～2033年の予測期間中に9.90％のCAGRで拡大し、2025年の3億7,870万米ドルから2033年には8億589万米ドルに成長すると予測されています。同市場の成長は、消化器がんの有病率の上昇、一般住民の意識の高まり、インドにおける腫瘍学研究への投資の増加に起因しています。Global Cancer Observatoryの推計によると、2022年には、胃がんはインドの男性で5番目に多いがん種で、全がん症例の6.2%を占めています。

インドでは、診断の遅れが大きな課題であり、非特異的な症状や、国内の農村部では診断サービスへのアクセスが限られていることが原因となっていることが多いです。その結果、患者は進行がんに罹患することが多く、より集中的な治療が必要となります。しかし、公衆衛生キャンペーンの高まりや高度な診断技術へのアクセスが、同国における早期発見率の向上に役立っています。さらに、インドのヘルスケア・インフラは、Ayushman Bharatのような政府の支援策と相まって、がん医療へのアクセスをさらに高めています。一方、医薬品開発における技術革新、バイオシミラーの導入、非公開病院と製薬会社とのパートナーシップの拡大は、市場に有利な成長機会をもたらすと期待されています。

当レポートでは、インドの胃がん治療市場について調査し、市場の概要とともに、治療タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 インドの胃がん治療市場の見通し、2019年～2033年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 治療タイプ別
    • 免疫療法
    • 標的療法
    • 化学療法
    • その他
  • タイプ別
    • 腺がん
    • 消化管間質腫瘍（GIST）
    • 胃食道接合部がん
  • 薬剤クラス別
    • PD-1/PD-L1阻害剤
    • HER2拮抗薬
    • VEGFR2拮抗薬
    • その他
  • 投与経路
    • 経口
    • 注射
  • 流通チャネル別
    • 病院薬局
    • 専門薬局および小売薬局
    • その他
  • 地域別
    • 北部
    • 東部
    • 西部と中央部
    • 南部
  • 企業別市場シェア分析（上位5社およびその他- 金額ベース、2025年）
• 2025年の市場マップ分析

第6章 需要供給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場の促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Novartis Healthcare Private Limited
  • Pfizer Limited
  • Mylan Pharmaceuticals Private Limited (Subsidiary of Viatris Inc.)
  • Merck & Co., Inc.
  • Roche Products (India) Private Limited
  • Teva India Private Limited
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Bristol Myers Squibb India Pvt Ltd
  • Samsung Bioepis Co., Ltd.
  • Celltrion Healthcare India Private Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Stomach Cancer Treatment Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Stomach Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 3. India Stomach Cancer Treatment Market Share (%), By Type, FY2019-FY2033F
• Figure 4. India Stomach Cancer Treatment Market Share (%), By Drug Class, FY2019-FY2033F
• Figure 5. India Stomach Cancer Treatment Market Share (%), By Route of Administration, FY2019-FY2033F
• Figure 6. India Stomach Cancer Treatment Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 7. India Stomach Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 8. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Drug Class Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 12. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 13. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

India stomach cancer treatment market is projected to witness a CAGR of 9.90% during the forecast period FY2026-FY2033, growing from USD 378.70 million in FY2025 to USD 805.89 million in FY2033. The market's growth can be attributed to the growing prevalence of gastrointestinal cancer, rising awareness among the general population, and increasing investments in oncology research in India. According to the estimates of the Global Cancer Observatory, in 2022, stomach cancer was the fifth most common type of cancer in men in India, accounting for 6.2% of all cancer cases.

In India, delayed diagnosis is a significant challenge, often caused due to non-specific symptoms and limited access to diagnostic services in rural areas in the country. This frequently results in patients presenting with advanced stages of cancer, requiring more intensive treatments. However, rising public health campaigns and access to advanced diagnostic technologies are helping increase early detection rates in the country. Additionally, India's expanding healthcare infrastructure, combined with government-backed initiatives such as Ayushman Bharat, is further increasing the accessibility of cancer care. Meanwhile, innovations in drug development, introduction of biosimilars, and increasing partnerships between private hospitals and pharmaceutical companies are further expected to provide lucrative growth opportunities for the market.

Rising Investments by Leading Hospitals Towards Cancer Care Boosts Market Growth

Hospitals across the country are allocating more resources for acquiring advanced diagnostic tools and technologies, utilizing cutting-edge treatment modalities, including immunotherapy and targeted therapy, and upgrading the oncology infrastructure. Such investments are enhancing the capacity of hospitals to provide comprehensive treatment, accurate diagnosis, and early detection, resulting in higher survival rates and improved patient outcomes. Hospital investments also foster clinical research, support the adoption of globally recognized practices, and facilitate participation in clinical trials, further supporting the market's expansion in the country.

For instance, in February 2025, Manipal Hospital, Baner, launched a preventive oncology clinic in order to empower the patient population with risk assessment, timely screening, and lifestyle counseling for improving treatment outcomes and performing a risk assessment to detect cancer at an early stage.

Introduction of Innovative Treatments and Public Health Policies Support Market Expansion

Rising efforts to bolster the availability of innovative therapies to combat stomach cancer in India in combination with the growing efforts of the government to increase the accessibility and affordability of various treatment solutions is one of the major drivers of the India stomach cancer treatment market. The introduction of immunotherapy drugs such as nivolumab and pembrolizumab for gastric cancer, which have shown improved survival rates, is reshaping treatment protocols.

Meanwhile, programs such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), which aims to integrate cancer screening into primary healthcare services, especially in underserved rural areas, further supporting the market's expansion. Moreover, initiatives such as the Pradhan Mantri Jan Arogya Yojana (PMJAY) are expanding access to cancer treatment by covering hospital expenses under government health insurance schemes, encouraging more patients to undergo treatment for stomach cancer, thereby increasing the market's demand.

Evolving Lifestyle is Driving the Market's Demand

The evolving lifestyle and eating habits in the country are one of the major drivers of the Indian stomach cancer treatment market. Habits such as increased consumption of processed foods, sedentary habits, rising obesity, chronic stress, and high salt intake are contributing to the high incidences of stomach cancer in India. Increasing preference for ordering junk food due to the associated convenience and preference for food products that have less fiber, high salt, and sugar, and are processed are also boosting the number of cases of stomach cancer in India. The gross order value for Zomato increased to USD 3.08 billion in FY2023 from USD 152.68 million in FY2018. The recognition of lifestyle's role in cancer risk is prompting public health initiatives and patient education, further increasing early diagnosis and treatment uptake.

Hospital Pharmacies Holds Major Market Share

Hospital pharmacies account for a major share of the India stomach cancer treatment market because hospitals serve as primary centers for cancer diagnosis, treatment, and management. Many stomach cancer patients in India require inpatient care for chemotherapy, targeted therapy, and immunotherapy administration, which are often delivered under strict medical supervision in hospital settings. Hospital pharmacies ensure immediate and reliable access to these essential oncology drugs, facilitating timely treatment and better patient outcomes. Additionally, leading hospital pharmacies across the country are focusing on mergers and acquisitions to expand their presence in the country and strengthen their position in the market. For instance, in March 2025, Apollo Healthco Limited, which operated the online platform Apollo 24/7 and the Apollo pharmacy chain, announced that it is planning on establishing 80-100 new outlets over the next two years across Bengal.

Impact of the U.S. Tariff on India Stomach Cancer Treatment Market

In April 2025, the government of the United States announced tariffs of 26% on Indian imports. However, pharmaceuticals were exempted from these tariffs. The decision highlights the importance placed on the role of generic and economically efficient life-saving medications in ensuring public health, national security, and economic stability. Exemption allows leading pharmaceutical companies to strengthen their presence in the industry, ensure the supply of essential medications, and focus on strategic partnerships, reinforcing their status in regional and global markets. They also ensure that the market players are able to provide affordable therapies for cancer both domestically and internationally.

Key Players Landscape and Outlook

The key players in the market are actively focusing on expanding their operations in India by investing in manufacturing and research and development sites across the country. For instance, Novartis AG invests approximately USD 400 million in its operations in India every year. This investment allows the company to focus on clinical trial operations and basic research and support the accelerated development and improved accessibility of innovative therapeutic solutions, such as immunotherapies and targeted treatments, to combat the growing threat of stomach cancer in India. Such investments by the key players of the market in the country's healthcare ecosystem are augmenting the growth of the market by ensuring the availability of advanced treatment solutions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. India Stomach Cancer Treatment Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Immunotherapy
    • 5.2.1.2. Targeted Therapy
      • 5.2.1.2.1. Biologics
      • 5.2.1.2.2. Biosimilar
    • 5.2.1.3. Chemotherapy
      • 5.2.1.3.1. Capecitabine
      • 5.2.1.3.2. Cisplatin
      • 5.2.1.3.3. Fluorouracil (5-FU)
      • 5.2.1.3.4. Oxaliplatin
      • 5.2.1.3.5. Others
    • 5.2.1.4. Others
  • 5.2.2. By Type
    • 5.2.2.1. Adenocarcinomas
    • 5.2.2.2. Gastrointestinal Stromal Tumors (GISTs)
    • 5.2.2.3. Gastroesophageal Junction Cancer
  • 5.2.3. By Drug Class
    • 5.2.3.1. PD-1/PD-L1 Inhibitors
    • 5.2.3.2. HER2 Antagonists
    • 5.2.3.3. VEGFR2 Antagonists
    • 5.2.3.4. Other Drug Classes
  • 5.2.4. By Route of Administration
    • 5.2.4.1. Oral
    • 5.2.4.2. Injectable
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Specialty and Retail Pharmacies
    • 5.2.5.3. Others
  • 5.2.6. By Region
    • 5.2.6.1. North
    • 5.2.6.2. East
    • 5.2.6.3. West and Central
    • 5.2.6.4. South
  • 5.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Treatment Type
  • 5.3.2. By Type
  • 5.3.3. By Drug Class
  • 5.3.4. By Route of Administration
  • 5.3.5. By Distribution Channel
  • 5.3.6. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Healthcare Private Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Pfizer Limited
  • 16.3.3. Mylan Pharmaceuticals Private Limited (Subsidiary of Viatris Inc.)
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. Roche Products (India) Private Limited
  • 16.3.6. Teva India Private Limited
  • 16.3.7. Eli Lilly and Company (India) Pvt. Ltd.
  • 16.3.8. Bristol Myers Squibb India Pvt Ltd
  • 16.3.9. Samsung Bioepis Co., Ltd.
  • 16.3.10. Celltrion Healthcare India Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer